US Pharma MarketingPatients with treatment-resistant depression are costing Medicare big
A patient with treatment-resistant depression (TRD) costs Medicare 21%, or $8,000, more annually than a patient with depression that is controlled. The report found that treatment-resistant depression patients cost Medicare about $46,000 annually, with the majority of costs attributed to hospitalizations and prescription costs.
The report found that treatment-resistant depression patients cost Medicare about $46,000 annually, with the majority of costs attributed to hospitalizations and prescription costs.
Source: Fierce Healthcare